Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia

Journal of Experimental Medicine

Volumn 189, Issue 7, 1999, Pages 1043-1052

  Lallemand Breitenbach, Valérie ^d   Guillemin, Marie Claude ^d   Janin, Anne ^a   Daniel, Marie Thérèse ^a   Degos, Laurent ^a   Kogan, Scott C ^b   Bishop, J Michael ^b   De Thé, Hugues ^a,c  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CNRS   (France)

^d NONE

Author keywords

Apoptosis; Cancer; Clinical trials; Differentiation; Transgenics

Indexed keywords

ARSENIC; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; LEUKEMIA CELL; LIVER SINUSOID; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; TRANSCRIPTION REGULATION; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ARSENIC; CELL DIFFERENTIATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HEMATOPOIESIS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LIVER; LUNG; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEINS, FUSION; REMISSION INDUCTION; SPLEEN; TRETINOIN; TUMOR CELLS, CULTURED; TUMOR STEM CELLS;

EID: 0033526012     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.189.7.1043     Document Type: Article

References (39)

1. Tsai, S., and S. Collins. 1993. A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocytic stage. Proc. Natl. Acad. Sci. USA. 90:7153-7157.
2. Labrecque, J., D. Allan, P. Chambon, N.N. Iscove, D. Lohnes, and T. Hoang. 1998. Impaired granulocytic differentiation in vitro in hematopoietic cells lacking RAR alpha1 and gamma. Blood. 92:607-615.
3. Lamond, A.I., and W.C. Earnshaw. 1998. Structure and function in the nucleus. Science. 280:547-553.
4. Mu, Z.M., K.V. Chin, J.H. Liu, G. Lozano, and K.S. Chang. 1994. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol. Cell. Biol. 14:6858-6867.
5. Koken, M.H.M., G. Linares-Cruz, F. Quignon, A. Viron, M.K. Chelbi-Alix, J. Sobczak-Thépot, L. Juhlin, L. Degos, F. Calvo, and H. de Thé. 1995. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene. 10:1315-1324.
6. Le, X.-F., P. Yang, and K.-S. Chang. 1996. Analysis of the growth and transformation suppressor domains of promyelocytic leukemia gene, PML. J. Biol. Chem. 271:130-135.
7. Quignon, F., F. De Bels, M. Koken, J. Feuteun, J.C. Ameisen, and H. de Thé. 1998. PML induces a caspase-independent cell death process. Nat. Genet. 20:2559-2565.
8. Borden, K.L.B. 1997. The promyelocytic leukemia protein PML has a pro-apoptotic activity mediated through its ring domain. FEBS Lett. 418:30-34.
9. Le, X.-F., S. Vallian, Z.-M. Mu, M.-C. Hung, and K.-S. Chang. 1998. Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis. Oncogene. 16: 1839-1849.
10. Brown, D., S. Kogan, E. Lagasse, I. Weissman, M. Alcalay, P.G. Pelicci, S. Atwater, and J.M. Bishop. 1997. A PML RAR alpha transgene initiates murine acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA. 94:2551-2556.
11. Grignani, F., P. Ferrucci, U. Testa, G. Talamo, M. Fagioli, M. Alcalay, A. Mencarelli, F. Grignani, C. Peschle, I. Nicoletti, and P. Pelicci. 1993. The acute promyelocytic leukemia-specific PML/RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 74:423-431.
12. Lin, R.J., L. Nagy, S. Inoue, W.L. Shao, W.H. Miller, and R.M. Evans. 1998. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 391:811-814.
13. Grignani, F., S. de Matteis, C. Nervi, L. Tomassoni, V. Gelmetti, M. Cioce, M. Fanelli, M. Ruthardt, F.F. Ferrara, I. Zamir, et al. 1998. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 391:815-818.
14. Daniel, M.-T., M. Koken, O. Romagné, S. Barbey, A. Bazarbachi, M. Stadler, M. Guillemin, L. Degos, C. Chomienne, and H. de Thé. 1993. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood. 82: 1858-1867.
15. Koken, M.H.M., F. Puvion-Dutilleul, M.C. Guillemin, A. Viron, G. Linares-Cruz, N. Stuurman, L. de Jong, C. Szostecki, F. Calvo, C. Chomienne, et al. 1994. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO (Eur. Mol. Biol. Organ.) J. 13:1073-1083.
16. Dyck, J.A., G.G. Maul, W.H. Miller, J.D. Chen, A. Kakizuka, and R.M. Evans. 1994. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell. 76:333-343.
17. Weis, K., S. Rambaud, C. Lavau, J. Jansen, T. Carvalho, M. Carmo-Fonseca, A. Lamond, and A. Dejean. 1994. Retinoic acid regulates aberrant nuclear localization of PML/RARα in acute promyelocytic leukemia cells. Cell. 76:345-356.
18. Testa, U., F. Grignani, P. Samoggia, C. Zanetti, R. Riccioni, F.L. Coco, D. Diverio, N. Felli, C.G. Passerini, M. Grell, et al. 1998. The PML/RARα fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts. J. Clin. Invest. 101:2278-2289.
19. Wang, Z.G., L. Delva, M. Gaboli, R. Rivi, M. Giorgio, C. Cordon-Cardo, F. Grosveld, and P.P. Pandolfi. 1998. Role of PML in cell growth and the retinoic acid pathway. Science. 279:1547-1551.
20. Quignon, F., Z. Chen, and H. de Thé. 1997. Retinoic acid and arsenic: towards oncogene-targeted treatments of acute promyelocytic leukaemia. Biochim. Biophys. Acta. 1333:M53-M61.
21. Look, A.T. 1998. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia. J. Natl. Cancer Inst. 90:86-88.
22. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/ PML proteins. Blood. 88:1052-1061.
23. Huang, M., Y. Ye, R. Chen, J. Chai, J. Lu, L. Zhoa, L. Gu, and Z. Wang. 1988. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukaemia. Blood. 72:567-572.
24. Muller, S., M.J. Matunis, and A. Dejean. 1998. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO (Eur. Mol. Biol. Organ.) J. 17:61-70.
25. Zhu, J., M.H.M. Koken, F. Quignon, M.K. Chelbi-Alix, L. Degos, Z.Y. Wang, Z. Chen, and H. de Thé. 1997. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA. 94:3978-3983.
26. Yoshida, H., K. Kitamura, K. Tanaka, S. Omura, T. Miyazaki, T. Hachiya, R. Ohno, and T. Naoe. 1996. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia. Possible role of the proteasome pathway. Cancer Res. 56:2945-2948.
27. Raelson, J.V., C. Nervi, A. Rosenauer, L. Benedetti, Y. Monczak, M. Pearson, P.G. Pelicci, and W.H. Miller. 1996. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood. 88:2826-2832.
28. Shao, W., M. Fanelli, F.F. Ferrara, R. Riccioni, A. Rosenauer, K. Davison, W. Lamph, S. Waxman, P.G. Pellici, F. Lo Coco, et al. 1998. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst. 90:124-133.
29. 3 exerts dose-dependent dual effects on APL cells. Blood. 89:3345-3353.
30. Gianni, M., M. Koken, M. Chelbi-Alix, G. Benoit, M. Lanotte, Z. Chen, and H. de Thé. 1998. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood. 91:4300-4310.
31. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 89:3354-3360.
32. Castaigne, S., N. Balitrand, H. de Thé, A. Dejean, L. Degos, and C. Chomienne. 1992. A PML/retinoic acid receptor alpha fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood. 79:3110-3115.
33. Rochette-Egly, C., S. Adam, M. Rossignol, J.-M. Egly, and P. Chambon. 1997. Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. Cell. 90:97-107.
34. Taneja, R., C. Rochette-Egly, J.L. Plassat, L. Penna, M.P. Gaub, and P. Chambon. 1997. Phosphorylation of activation function AF1 and AF2 of RAR alpha and RAR gamma is indispensable for differentiation of F9 cells upon retinoic acid and cAMP treatment. EMBO (Eur. Mol. Biol. Organ.) J. 16: 6452-6465.
35. Soignet, S., P. Maslak, Z.G. Wang, S. Jhanwar, E. Calleja, L. Dardashti, D. Corso, A. DeBlasio, J. Grabrilove, D. Scheinberg, et al. 1998. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339:1341-1350.
36. Warrell, R., H. de Thé, Z. Wang, and L. Degos. 1993. Acute promyelocytic leukemia. N. Engl. J. Med. 329:177-189.
37. Nason-Burchenal, K., D. Gandini, M. Botto, J. Allopenna, J.R.C. Seale, N.C.P. Cross, J.M. Goldman, E. Dmitrovsky, and P.P. Pandolfi. 1996. Interferon augments PML and PML/RAR alpha expression in normal myeloid and acute promyelocytic cells and cooperates with all-trans retinoic acid to induce maturation of a retinoid-resistant promyelocytic cell line. Blood. 88:3926-3932.
38. Melcher, A., S. Todryk, N. Hardwick, M. Ford, M. Jacobson, and R.G. Vile. 1998. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med. 5:581-587.
39. Degos, L., H. Dombret, C. Chomienne, M.T. Daniel, J.M. Miclea, C. Chastang, S. Castaigne, and P. Fenaux. 1995. All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood. 85:2643-2653.